-
Je něco špatně v tomto záznamu ?
Efficacy of switches within the class of IL-17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (BIOREP)
M. Tichy, M. Kojanova, B. Velackova, T. Dolezal, S. Gkalpakiotis, P. Cetkovska, BIOREP study group
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
PubMed
36065488
DOI
10.1111/dth.15772
Knihovny.cz E-zdroje
- MeSH
- biologická terapie MeSH
- cytokiny MeSH
- interleukin-17 * MeSH
- lidé MeSH
- monoklonální protilátky terapeutické užití MeSH
- psoriáza * chemicky indukované farmakoterapie MeSH
- registrace MeSH
- stupeň závažnosti nemoci MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
The IL-17 cytokine family encompasses six different homodimers and heterodimers referred to as IL-17A-F. Due to some differences in the mechanism of IL-17 inhibition, aninsufficient effect of one IL-17 inhibitor does not necessarily imply lack of efficacy of the other agent of the same class. Aim of study was analysis of the success rate of switches among IL-17 inhibitors (secukinumab, ixekizumab, and brodalumab) in patients treated in the Czech Republic. Data were obtained from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (BIOREP). Our analysis involved data of a total of 90 patients with severe chronic plaque psoriasis and baseline PASI scores >10 both prior to first-line biological therapy initiation and after switch to another agent of the class of IL-17 inhibitors. The most effective switch was that from secukinumab to brodalumab, with PASI 90 reached by 64.7% and 73.3% of patients at weeks 12 and 24. Among patients switched from secukinumab to ixekizumab target PASI 90 responses were achieved (at weeks 12 and 24) by 41.2% and 55.2% of patients. Among patients switched from ixekizumab to brodalumab target PASI 90 responses were achieved, at the above time points, by 30.8% and 38.5% of patients. Our analysis showed a high success rate of switches from secukinumab to ixekizumab and brodalumab, followed by the ixekizumab-to-brodalumab switch. Importantly, the therapeutic response and success rates of individual switches are independent of the patient's body weight and presence of psoriatis arthritis.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22033172
- 003
- CZ-PrNML
- 005
- 20230131151130.0
- 007
- ta
- 008
- 230120s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/dth.15772 $2 doi
- 035 __
- $a (PubMed)36065488
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Tichy, Martin $u Department of Dermatology and Venereology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic $1 https://orcid.org/0000000249252634
- 245 10
- $a Efficacy of switches within the class of IL-17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (BIOREP) / $c M. Tichy, M. Kojanova, B. Velackova, T. Dolezal, S. Gkalpakiotis, P. Cetkovska, BIOREP study group
- 520 9_
- $a The IL-17 cytokine family encompasses six different homodimers and heterodimers referred to as IL-17A-F. Due to some differences in the mechanism of IL-17 inhibition, aninsufficient effect of one IL-17 inhibitor does not necessarily imply lack of efficacy of the other agent of the same class. Aim of study was analysis of the success rate of switches among IL-17 inhibitors (secukinumab, ixekizumab, and brodalumab) in patients treated in the Czech Republic. Data were obtained from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (BIOREP). Our analysis involved data of a total of 90 patients with severe chronic plaque psoriasis and baseline PASI scores >10 both prior to first-line biological therapy initiation and after switch to another agent of the class of IL-17 inhibitors. The most effective switch was that from secukinumab to brodalumab, with PASI 90 reached by 64.7% and 73.3% of patients at weeks 12 and 24. Among patients switched from secukinumab to ixekizumab target PASI 90 responses were achieved (at weeks 12 and 24) by 41.2% and 55.2% of patients. Among patients switched from ixekizumab to brodalumab target PASI 90 responses were achieved, at the above time points, by 30.8% and 38.5% of patients. Our analysis showed a high success rate of switches from secukinumab to ixekizumab and brodalumab, followed by the ixekizumab-to-brodalumab switch. Importantly, the therapeutic response and success rates of individual switches are independent of the patient's body weight and presence of psoriatis arthritis.
- 650 _2
- $a monoklonální protilátky $x terapeutické užití $7 D000911
- 650 _2
- $a biologická terapie $7 D001691
- 650 _2
- $a cytokiny $7 D016207
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a interleukin-17 $7 D020381
- 650 12
- $a psoriáza $x chemicky indukované $x farmakoterapie $7 D011565
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a výsledek terapie $7 D016896
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kojanova, Martina $u Department of Dermatovenereology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic
- 700 1_
- $a Velackova, Barbora $u Value Outcomes, Prague, Czech Republic
- 700 1_
- $a Dolezal, Tomas $u Value Outcomes, Prague, Czech Republic
- 700 1_
- $a Gkalpakiotis, Spyridon $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000269565961
- 700 1_
- $a Cetkovska, Petra $u Department of Dermatovenereology, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic
- 710 2_
- $a BIOREP study group
- 773 0_
- $w MED00005384 $t Dermatologic therapy $x 1529-8019 $g Roč. 35, č. 10 (2022), s. e15772
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36065488 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151126 $b ABA008
- 999 __
- $a ok $b bmc $g 1891752 $s 1184507
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 35 $c 10 $d e15772 $e 20220905 $i 1529-8019 $m Dermatologic therapy $n Dermatol Ther $x MED00005384
- LZP __
- $a Pubmed-20230120
